Faegre Drinker Biddle & Reath LLP, a Delaware limited liability partnership | This website contains attorney advertising.
August 2023

Semaglutide: What to Know Before Compounding


In the National Association of Boards of Pharmacy’s (NABP) Innovations publication, government and regulatory partner Libby Baney and counsel Jonathan Keller, PharmD, coauthored an article on what boards of pharmacy and other stakeholders should know about compounded semaglutide products.

In the article, Baney and Keller provide an overview of semaglutide, the scenarios in which it can be compounded, and the criteria for compounding. The authors also outline issues to consider before compounding semaglutide, actions taken by boards of pharmacy, and what comes next.

Read the Full Article

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.